Korea Tries To Buffer Heavy Price Cuts With R&D Incentives, But Local And Global Pharma Up In Arms
This article was originally published in The Pink Sheet Daily
Executive Summary
South Korea's Ministry of Health and Welfare announced measures to drastically cut drug prices, while also committing to support innovation-focused companies through tax credits and preferential pricing, but both domestic and global pharma reacted with strongly worded opposition.